Home / North America · United States / Biotech (synthetic biology / gene editing) · Private

Colossal Biosciences

AI-generated working estimate based on public information / opinion & commentary, not a statement of fact / corrections & rebuttals welcome / Change log / Contact

Colossal Biosciences

Synthetic biology flying a 'de-extinction' banner—conservation, or contested spectacle

On hold
NARRATIVE VALUE
Certainty
●○○ low
ABCDEFG

The assessment is on hold, awaiting a build-up of confirmed evidence.= non-additive meter

As of: 2026-Q3Status: ActiveCeiling reason: No confirmed minus (a projected, contested stage; both the conservation plus and the animal-welfare / conservation-hindrance minus are unconfirmed).
History2026-Q3HHistory grows each quarter

Colossal Biosciences: Synthetic biology flying a 'de-extinction' banner—conservation, or contested spectacle. At present independent evidence is scarce, so the assessment is on hold. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)

Main narrative

Colossal Biosciences is a biotech founded in 2021 in Dallas, Texas, by Harvard geneticist George Church and Ben Lamm, calling itself 'the world's first de-extinction and conservation company.' It made a 'woolly mouse' edited with woolly-mammoth traits, and in 2025 claimed to have 'brought back' the extinct dire wolf, unveiling three pups (Romulus, Remus, Khaleesi) with about 14 edited gray-wolf genes on a private 2,000-acre preserve. The company is for-profit, valued at about $10.2B, having raised about $440M, and monetizes technology it develops by spinning it off to firms like Form Bio. Its banner is not only de-extinction itself but the claim that the gene-editing and cloning technology it cultivates can also save currently living endangered species, and an ecosystem-restoration story such as mammoths preserving permafrost to curb warming.

One person’s story (N1)

+ A single story

A +N1 (one person’s story) will be added once an independent source is confirmed.

Positive / negative effects

+ effects

  • See the N1 above for the main positive story; independently verified + will be added over time.

− effects (confirmed)

  • No confirmed −.
Watching (unconfirmed; not counted in the assessment)
  • M
  • a
  • n
  • y
  • s
  • c
  • i
  • e
  • n
  • t
  • i
  • s
  • t
  • s
  • '
  • c
  • r
  • i
  • t
  • i
  • q
  • u
  • e
  • o
  • f
  • '
  • n
  • o
  • t
  • a
  • d
  • i
  • r
  • e
  • w
  • o
  • l
  • f
  • /
  • n
  • o
  • e
  • c
  • o
  • l
  • o
  • g
  • i
  • c
  • a
  • l
  • v
  • a
  • l
  • u
  • e
  • '
  • ;
  • a
  • n
  • i
  • m
  • a
  • l
  • -
  • w
  • e
  • l
  • f
  • a
  • r
  • e
  • c
  • o
  • n
  • c
  • e
  • r
  • n
  • f
  • o
  • r
  • r
  • e
  • c
  • r
  • e
  • a
  • t
  • e
  • d
  • i
  • n
  • d
  • i
  • v
  • i
  • d
  • u
  • a
  • l
  • s
  • ;
  • d
  • i
  • v
  • e
  • r
  • s
  • i
  • o
  • n
  • o
  • f
  • r
  • e
  • s
  • o
  • u
  • r
  • c
  • e
  • s
  • /
  • a
  • t
  • t
  • e
  • n
  • t
  • i
  • o
  • n
  • f
  • r
  • o
  • m
  • c
  • o
  • n
  • s
  • e
  • r
  • v
  • a
  • t
  • i
  • o
  • n
  • ;
  • c
  • o
  • n
  • c
  • e
  • r
  • n
  • i
  • t
  • i
  • s
  • u
  • s
  • e
  • d
  • ,
  • v
  • i
  • a
  • f
  • a
  • l
  • s
  • e
  • h
  • o
  • p
  • e
  • ,
  • t
  • o
  • p
  • o
  • l
  • i
  • t
  • i
  • c
  • a
  • l
  • l
  • y
  • r
  • o
  • l
  • l
  • b
  • a
  • c
  • k
  • e
  • n
  • d
  • a
  • n
  • g
  • e
  • r
  • e
  • d
  • -
  • s
  • p
  • e
  • c
  • i
  • e
  • s
  • p
  • r
  • o
  • t
  • e
  • c
  • t
  • i
  • o
  • n
  • (
  • E
  • S
  • A
  • )
  • ;
  • f
  • o
  • r
  • -
  • p
  • r
  • o
  • f
  • i
  • t
  • V
  • C
  • ,
  • h
  • u
  • g
  • e
  • v
  • a
  • l
  • u
  • a
  • t
  • i
  • o
  • n
  • ,
  • a
  • n
  • d
  • d
  • e
  • p
  • e
  • n
  • d
  • e
  • n
  • c
  • e
  • o
  • n
  • m
  • e
  • d
  • i
  • a
  • e
  • x
  • p
  • o
  • s
  • u
  • r
  • e
  • .
Looking ahead (not included in the assessment)
  • Correcting the distance between the 'de-extinction' claim and reality (gene-edited individuals); an actual record of transferring developed technology to living-species conservation; verifying animal welfare and ecological meaning; avoiding the side effects of diverted conservation resources and false-hope-driven protection rollback.

A second look

This is a for-profit venture at a projected, contested stage, with both plus and minus unconfirmed. The claimed plus (conservation, ecosystem restoration, transfer of the technology to living-species conservation) is mostly a future promise, and what it has realized is fiercely disputed—many scientists (Lynch, Shiffman, Hochuli, Coltman, etc.) criticize that the unveiled animals are 'not dire wolves but gray wolves with 14 edited genes,' living on a private preserve with 'no ecological value' (the dire wolf is a separate genus, Aenocyon, diverged about 5.7 million years ago). The minus is also contested: animal-welfare concerns that recreated individuals suffer; worry that limited conservation resources and attention are diverted; and that the false hope 'extinction is reversible' weakens habitat protection—actually used as a political pretext to justify rolling back the US Endangered Species Act (Rep. Boebert, Interior Secretary Burgum). Because the distance between the story (de-extinction/conservation) and verified reality is large, and neither the plus's existence nor the minus's degree can be pinned down, it can be placed neither at B nor out-of-range. Hence on hold (certainty = low).

Sources

C&EN(American Chemical Society)|2025-04-14|🔗
Colossal/NPR/Fast Company|2026-03-04|🔗
2026-03-02|🔗

How to read this assessment

A Independently verified +, with no confirmed −
B Leans +, with independent backing
C Mixed. A confirmed − sets the ceiling, or much is unverified
D A serious confirmed − sets the ceiling
E A serious − reaches the core of the organization
F Serious and systemic, with little redeeming +
G Only extreme cases
Out of scope An entity whose core purpose is illegal
On hold Independent evidence is scarce on both + and −
  • Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
  • The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
  • Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
  • The letter (assessment) and certainty (how reliable the information is) are separate axes.

This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.

Terms: Narrative Value = an assessment (A–G) of the distance between the story an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top